25 ¶ Timothy P. Stinear and Benjamin P. Howden are joint senior authors and contributed equally 26 to this work. 27 28 KEY WORDS: antibiotic resistance, resistance mutations, deep-sequencing, Staphylococcus 29 aureus, Mycobacterium tuberculosis, rifampicin, daptomycin 30 31 2 ABSTRACT 32 Acquired mutations are a major mechanism of bacterial antibiotic resistance generation and 33 dissemination, and can arise during treatment of infections. Early detection of sub-populations 34 of resistant bacteria harbouring defined resistance mutations could prevent inappropriate 35 antibiotic prescription. Here we present RM-seq, a new amplicon-based DNA sequencing work-36 flow based on single molecule barcoding coupled with deep-sequencing that enables the high-37
resistance mutations after a selection bottleneck detected antimicrobial cross-resistance and 48 collateral sensitivity-conferring mutations. Using a mouse infection model and human clinical 49 samples, we also demonstrate that RM-seq can be effectively applied in vivo to track complex 50 mixed populations of S. aureus and another major human pathogen, Mycobacterium tuberculosis 51 during infections. RM-seq is a powerful new tool to both detect and functionally characterise 52 mutational antibiotic resistance. 53
INTRODUCTION 54
Antimicrobial resistance is on the rise and is responsible for millions of deaths every year 55 (World Health Organization 2014). Bacterial populations consistently and rapidly overcome the 56 challenge imposed by the use of a new antibiotic. Their remarkable ability to quickly develop 57 resistance is due to their capacity to exchange genes and to their high mutation supply rate. as Mycobacterium tuberculosis, resistance to all therapeutic agents is mediated by 76 mutations (Smith et al. 2013) . 77 78 Resistance mutations can be effectively selected in vitro, and so genome sequence comparisons 79 of resistant clones derived from sensitive ancestral clones after antibiotic exposure have 80 permitted the identification of numerous resistance-associated mutations (Feng et al. 2009 ; 81 Livermore et al. 2015; Chen et al. 2014; Mwangi et al. 2007 ). From these studies it is apparent 82 that the mutational landscape for a single antibiotic combination within a specific bacterium 83 can be broad (Howden et replication, translation, transcription and cell-wall metabolism regulation, mutations arising in 92 these genes have been associated with a broad range of pleiotropic effects in addition to the 93 antibiotic resistance that they cause (Hershberg 2017 ). An increasing body of literature shows 94 that antibiotic resistance mutations can lead to broader negative therapeutic consequences 95 However, there is currently no efficient method to identify pleiotropic mutations. 100
Comprehensively identifying mutations associated with antibiotic cross-resistance and 101 increased risk of therapeutic failure will provide crucial information for future personalised 102 medicine and will help to improve therapeutics guidelines through a greater understanding of 103 the drivers and consequences of mutational resistance. At an epidemiological and evolutionary 104 7 error correction of the sequenced DNA and thus high confidence in calling of a resistance 139 associated mutations that might occur at a frequency well below the inherent error rate (~1% 140 (Schirmer et al. 2015) ) of the sequencer. Secondly, it permits accurate quantification of allele 141 frequencies by correcting for the amplification bias introduced during the exponential PCR step. 142
The RM-seq bioinformatics pipeline takes as input the raw reads and outputs a table of all 143 annotated substitutions, insertions and deletions identified in the selected population given the 144 original sequence (the target locus sequence before selection). A diagram of the steps in the 145 data analysis pipeline is presented in Fig 1C ( 
populations. 167
To assess the capability of the RM-seq protocol to detect and quantify rare genetic variants from 168 mixed populations of resistant bacteria, we first evaluated its error correction efficiency. We 169 sequenced at high depth a 270 bp region comprising the rifampicin resistance determining 170 region (RRDR) of a S. aureus rifampicin susceptible isolate (wild-type strain NRS384). By 171 counting incorrect nucleotide calls at each position after aligning raw reads to the WT sequence, 172
we found an average error rate per position of 2.8 x 10 -2 ± 1.7 x 10 -2 (standard deviation [SD]), 173 which is commonly observed for the Miseq instrument (Schirmer et al. 2015) . Merging forward 174 and reverse reads reduced the error rate by an order of magnitude to 5.6 x 10 -3 ± 4.4 x 10 -3 (SD). 175
By reconstructing consensus reads supported by at least 10 reads, the RM-seq further reduced 176 the error rate by three orders of magnitude to 1.16 x 10 -5 ± 3.1 x 10 -5 (SD) (Fig 2A) . At the protein 177 level no further mutations were observed among the 16,516 consensus reads generated (error 178 rate < 6 x 10 -5 ). 179
180
We then tested the performance of RM-seq genetic variant quantification on a defined 181 population of genetically reconstructed rifampicin resistant clones. Six different double or 182 single nucleotide variants (SNV) representing different rifampicin resistant rpoB mutants were 183 mixed at a relative CFU frequency of 0.9, 0.09, 0.009, up to 0.000009. We applied RM-seq 184 protocol three times independently from three different genomic DNA extractions obtained 185 from this mock community. After library preparation and sequencing on the Illumina MiSeq 186 platform, we obtained 1.8 -2.2 million raw reads per library, which yielded between 32,433 and 187 35,496 error-corrected consensus reads, supported by 10 reads or more. At this sequencing 188 depth the mutants ranging from a relative frequency of ~1 to 10 -4 were readily identified in all 189 three replicates. The normalised count of the different mutants showed little variation between 190 the replicate experiments ( Fig 2B) and we observed a very good correlation between the 191 expected mutant frequencies and the observed frequencies after RM-seq ( Fig 2C) . We also 192 assessed the technical variability of the detection and quantification of RM-seq by 193 independently processing three times the same complex population of in vitro selected resistant 194 clones (~10,000 colonies). The relative standard error (RSE) of variant quantification ranged 195 from 0.3% for the most frequent to 38% for rarest variants and the median RSE was 11% ( 
RM-seq and the dashed line represent the perfect correlation between expected and observed 209

frequencies. D. Quantification of S. aureus rpoB mutants from a complex population of in vitro 210
selected rifampicin resistant mutants. Columns represent mean normalised counts of the different 211 rpoB mutations that were observed among all triplicates, and error bars represent SEM. 212
High-throughput identification of rifampicin resistance mutations. 213
In order to comprehensively characterise the mutational repertoire associated with rifampicin 214 resistance we applied RM-seq on the RRDR of three independent pools of ~10,000 colonies 215 capable of growing on agar supplemented with 0.06 mg/L of rifampicin (European Committee 216 on Antimicrobial Susceptibility Testing [EUCAST] non-susceptibility clinical breakpoint). In 217 total, we identified 72 different predicted protein variants; among these 34 were identified in 218 the three independent resistant populations, 17 variants were identified among two resistant 219 populations, and 21 were identified in a single selection experiment (Fig 3) . According to our 220 recent extensive literature review of the alleles previously associated with rifampicin resistance 221 By looking at the different mutated positions, 21 amino-acid positions were repeatedly affected 225 along the RRDR with a similar pattern of mutation frequency at these positions. We observed 226 that 11 different amino acid positions have never previously been associated with rifampicin 227 resistance. The 3D structure modelling of S. aureus RpoB protein from E. coli RpoB-rifampicin 228 structure showed that the mutated positions were all in close proximity (≤10 A ) to the 229 rifampicin binding pocket of the beta-subunit of the RNA polymerase 230 (Supplemental_Fig_S1.pdf). Therefore, amino-acid sequence alteration at these positions are 231 likely to reduce the rifampicin-RNA polymerase affinity and thus to promote resistance. 232
Interestingly several residues in close proximity to the rifampicin binding pocket were never 233 affected, suggesting that amino acid substitution at these locations do not impair rifampicin 234 binding or that functional constraints make changes to these positions lethal for S. aureus. The 235 vast majority of the variants led to amino acid substitutions and several positions, such as 471 236 and 481 were found to be affected by a high number of different substitutions (11 and 12 237 respectively). We also observed one complex insertion (S464QF) and eight different deletions. 238
Positions 485 and 487 represented deletion hot-spots, as they were affected by single, triple 239 and quadruple residue deletions (L485., LSA485., LSAL485.) and single and double deletions 240 (A487. and AL487.), respectively. 241
We used allelic exchange and site-directed mutagenesis in the WT susceptible background 242 (rifampicin MIC 0.012 mg/L) to reconstruct 19 different rpoB alleles that were identified by RM-243 seq. After whole genome sequencing was used to ensure no secondary non-synonymous 244 mutations or insertion/deletion were introduced (Supplemental_Table_S1.pdf), we confirmed 245 that all these mutations resulted in rifampicin non-susceptibility or resistance with rifampicin 246 concentration thresholds and therefore would be classified as resistance-conferring mutations 277 by both guidelines. Among the 19 other mutations detected, four were associated with 278 resistance levels ranging from 1 to 4 mg/L, three with resistance ranging from 0.5 to 1 mg/L 279 and the remaining 12 with resistance ranging from 0.006 to 0.5 mg/L. Interestingly, S. aureus 280 with any of these last 12 alleles, selected only at low antibiotic concentrations, would be 281 classified as non-susceptible by EUCAST and susceptible by CLSI. Similarly, S. aureus with three 282 mutations associated with resistance by EUCAST would be classified as susceptible by CLSI ( Fig  283   4) . 284
285
We used mutants reconstructed by allelic-exchange to verify that the resistance level predicted 286 by RM-seq matched the MIC conferred by a particular allele. Among 17 reconstructed mutants 287 tested, 16 showed MICs in complete accord with the RM-seq prediction 288 (Supplemental_Table_S2.pdf). One mutant (D471G) with a borderline measured MIC of 0.5 289 mg/L was predicted to have an MIC superior to 0.5 and inferior or equal to 1 despite showing 290 clear reduction in abundance on 0.5 mg/L plate by RM-seq (Fig 4) . In order to evaluate if RM-seq can be used to characterise pleiotropic resistance mutations that 307 confer an increased or decreased susceptibility to a second antibiotic (cross-resistance or 308 collateral sensitivity respectively), we followed the differential abundance of resistance 309 mutations of a complex rifampicin resistant population after selection with a second antibiotic, 310 daptomycin. We chose daptomycin because it is a last-line antibiotic used against multidrug 311 at 3 hours represented 1.6% (± 0.1 SEM) of the initial inoculum and bacterial regrowth was 320 observed to 8.8% (± 6.9 SEM) at 24 hours ( Fig 5A) . The abundance of all rifampicin resistance 321 mutations were then quantified by RM-seq for the initial bacterial population (the inoculum) 322 and the surviving population at three hours and 24 hours after daptomycin exposure for the 323 three independent killing experiments ( Fig 5B) . 324
325
We tested for significant differential abundance of all the different mutations detected ( Fig 5C) . 326
After 3 hours of daptomycin treatment, one mutation appeared to increase in frequency 327 (Q468K) and another decreased (P519L) but the null hypothesis (no change) could not be 328 rejected (p>0.05 after correction for multiple testing [Wald test]). At 24 hours of daptomycin 329 selection, differential abundance of these two mutations increased, together with 10 other 330 rifampicin resistance mutations when compared with the mutant abundance in the initial 331 population ( Fig 5D) . All the rifampicin resistance mutations that were previously identified as 332 conferring decreased susceptibility to daptomycin (n=6) were found enriched after daptomycin In order to validate the use of RM-seq as a screening method to identify new mutations that 339 confer cross-resistance or collateral sensitivity we introduced in the wild-type strain by allelic 340 exchange seven rifampicin resistant mutations that were significantly enriched and three 341 mutations that were significantly rarefied after daptomycin selection. Among these mutations, 342
MIC testing validated six of the seven rifampicin resistance mutations as decreasing 343 susceptibility to daptomycin and one mutation as increasing the daptomycin susceptibility 344 (Supplemental_Table_S2.pdf). We then performed daptomycin time kill assays and found that 345 even though the D471E mutation did not show a decreased MIC to daptomycin 346 (Supplemental_Table_S2.pdf), this mutant was less tolerant to daptomycin ( Fig 5E) , concordant 347 with the RM-seq prediction which demonstrated reduced abundance of this mutation after 348 daptomycin exposure ( Fig 5D) . Similarly, rifampicin resistance mutations L488S, G489V, A477V 349 and Q468K were clearly associated with increased tolerance to daptomycin killing ( Fig 5E) . clone, we observed that within a given mouse different organs were infected with the same 394 clones. 395
396
We then infected mice with an inoculum comprising an equal amount of 10 reconstructed RpoB 397 mutants together with the wild-type susceptible strain. After 7 days of infection four mice were 398 analysed for RpoB mutant abundance by RM-seq. As observed in the previous experiment, the 399 wild-type allele did not persist after 7 days, showing that resistant clones are not outcompeted 400 by the wild-type clone for persistence in the mouse model; even without antibiotic selective 401 pressure ( Fig 6) . Three out of four mice were infected with clones encoding the H481N 402 mutation, which has been found to be the most frequent mutation among sequenced S. aureus 403 human isolates (Gue rillot et al. 2018), two had the L466S, H481N double mutation and one had 404 H481N only. Intriguingly, because the mice were infected simultaneously with 11 different 405 clones, the probability is low that at least two mice would become infected with the L466S, 406 H481N by chance (p=0.043). The probability is also low that at least three mice would become 407 randomly infected by a clone encoding the H481N mutation (p=0.057). Given the relatively 408 small number of mice investigated here, no conclusions can be drawn on the potential 409 competitive advantage of specific resistance mutations in vivo. Nevertheless, we show here that The multiple changes that were made to the treatment regimen are summarized in Fig 7. Using 444 RM-seq we found four other low frequencies rpoB mutants in addition to the dominant rpoB-445 S450L alleles previously associated with rifampicin resistance in this case (Fig 7) In this study, we designed and validated a new high-throughput workflow call RM-seq that 478 enables fast and comprehensive characterisation of antibiotic resistance mutations. We show 479 that a straightforward molecular PCR-based barcoding step coupled with high throughput 480
sequencing significantly reduces background sequencing noise and permits accurate 481 identification and quantification of rare resistance mutations in complex bacterial populations. 482
By applying RM-seq on large pools of in vitro selected rifampicin resistant S. aureus clones, we 483 demonstrate that the mutational resistome of a resistance locus can be defined. We found that 484 the range of rifampicin resistance mutations in S. aureus is broader than previously understood, 485
highlighting the inadequacy of our understanding of the genetic basis of resistance. Here, 72 486 mutations were associated with rifampicin resistance in S. aureus. In comparison, the CARD 487 database of antibiotic resistance markers only contains 6 rifampicin resistance mutations 488 (McArthur et al. 2013 ). As the RM-seq protocol can be applied on any combination of 489 microorganisms and resistance, its use has the potential to greatly enhance current knowledge 490 on microbial adaptation to antibiotic exposure. 491
492
One limitation of RM-seq is the size limit of the sequenced region that can be interrogated by a 493 single amplicon (270 bp with fully overlapping reads). This limitation is imposed by the 494 maximum read length of Illumina ® paired-end sequencing technology. Nevertheless, because 495 RM-seq is compatible with standard Nextera ® indexing primers, up to 384 resistance targets 496 can be multiplexed in a single sequencing run. Furthermore, when performing read sub-497 sampling simulation, we found that the number of high quality consensus reads increase almost 498 linearly with the number of reads when performing low depth sequencing 499 (Supplemental_Fig_S2.pdf). As little as 140,000 reads would be sufficient to obtain 10,000 500 consensus reads supported by 10 reads. Theoretically, all resistance variants arising among 501 more than 350 different targeted regions of 270 bp would be accurately identified from a mixed 502 population 1000 bacterial clones using a single MiSeq run (94500bp, ~86 different genes). This 503 kind of experimental design would be valuable to characterise the genetic basis of poorly 504 defined resistance mechanisms or to determine all the resistance mutation arising in a 505 particular gene. During the preparation of this manuscript, we scanned the full genes mprF 506 (2523 bp) and cls2 (1482 bp) for mutations conferring daptomycin resistance in S. aureus by 507 sequencing 10 and six amplicons respectively (manuscript in preparation). For the 508 development of diagnostic tool multiple resistance hotspots could be assessed by RM-seq using 509 a similar design. 510
511
The application of RM-seq is not restricted to the high-throughput identification of resistance 512 mutations and can also be used to characterise the phenotypic impact of specific resistance 513 mutations. We demonstrate here that differential mutation abundance analysis can be 514 performed to link subsets of mutations with clinical resistance breakpoints and to identify 515 resistance mutations that favour survival or multiplication in particular conditions. 516
Comparisons of allele frequencies in mixed populations before and after exposure to a second 517 antibiotic permitted the identification of specific resistance mutations that confer cross-518 resistance and collateral sensitivity. The demonstration that several specific rifampicin 519 resistance mutations can prevent bacterial clearance by daptomycin in vitro can have potential 520 clinical implication regarding the usage rifampicin and daptomycin in combination therapy. A 521 deeper understanding of how evolution of microbial resistance towards a given antibiotic 522 influences susceptibility or resistance to other drugs would have profound impact as it could be 523 We also showed that the persistence of resistance alleles can be followed during experimental 528 infection (murine blood stream infection model). As it is known that specific resistance 529 mutations can favour pathogenesis and immune evasion (Beceiro et al. 2013; Gao et al. 2013; 530 Baek et al. 2015), RM-seq can be used to screen for resistance mutations that increase or 531 decrease survival against ex vivo selective pressures (eg. whole blood killing, phagocytosis, 532 antimicrobial peptide killing, complement killing) or that favour colonisation or tissue invasion 533 (eg. biofilm formation, cell attachment, intracellular persistence). A better characterisation of 534 critical resistance mutations that confer cross-resistance or that impact pathogenesis would 535 permit both improving antibiotic resistance surveillance and drug management if a higher 536 therapeutic risk is confirmed. seq detection is not conditional on the affinity of short DNA probes, therefore all sensitive and 554 resistant variant can be detected and differentiated at the sequence level. Therefore, diagnostic 555 tools based on molecular barcoding and deep sequencing have the potential to perform better 556 than current state of the art diagnostic tests by accurately detecting pre-existing rare resistant 557 sub-population as well as uncommon resistance mutations. 558
559
We expect that RM-seq will be a valuable tool for the comprehensive characterisation of the 560 mutational resistance repertoire. A deeper understanding of resistance at the DNA level will be 561 the basis for improved genomic surveillance of antibiotic resistant pathogens, optimised 562 antibiotic treatment regimens, and can ultimately lead to precision medicine approaches for 563 treating microbial infections. 564
30
METHODS
565
In vitro selection of rifampicin resistant clones. 566
All experiments were conducted with S. aureus USA300 strain NRS384, acquired from BEI 567 resources. Rifampicin resistant colonies were selected from 20 independent overnight Heart 568 Infusion (HI) 10 mL broth cultures (5x10 9 CFU/mL) inoculated from single colonies. Cultures 569 were pelleted at 10 min at 3000 g and re-suspended in 200 µL of HI broth (2.5x10 11 CFU/mL). 570
These concentrated overnight cultures were then pooled and plated on HI plates supplemented 571 with rifampicin at 0.006, 0.5, 1 and 4 mg/L. Given that the spontaneous resistance rate for 572 rifampicin in S. aureus is ~2x10 -8 (O'Neill et al. 2001), 20 to 30 plates inoculated with 75 µL 573 were necessary to recover ~10,000 resistant clones after 48h incubation at 37°C. All resistant 574 colonies were recovered by scraping the plate flooded with 2 mL of Phosphate Buffered Saline 575 (PBS). After washing the pooled clone libraries in PBS, aliquots were used for genomic DNA 576 extraction and RM-seq library preparation and stocked in 25% glycerol at -80°C. 577 578
Amplicon library preparation and deep-sequencing. 579
Genomic DNA was extracted from 1 mL aliquots adjusted to an OD600 of 5 in HI broth. Cells were 580 pelleted and washed twice in PBS and genomic DNA was extracted using the DNeasy Blood & 581 Tissue Kit (QIAGEN). Random 16 bp barcodes were introduced by performing 8 cycles of linear 582 PCR with the primer x_RMseq_F (Supplemental_Table_S3.pdf) using the following PCR mix: 2 µL 583 of x_RMseq_F (5nM), 1 µL of genomic DNA (6 ng/µL), 12.5 µL Phusion® High-Fidelity PCR 584
Master Mix (2X, New England BioLabs Inc.), 6 µL H20. The following PCR cycle conditions were 585 used: 30 sec at 98°C, then 8 cycles of 10 sec at 98°C, 30 sec at 50°C, 30 sec 72°C, and a 2 min 586 elongation step at 72°C. Following the final cycle of the linear PCR, samples were cooled to 25°C 587 and the nested exponential PCR were performed by immediately adding 3.5 µL of a primer mix 588 containing 2 µL of primerx _RMseq_R (100 nM), 0.6 µL forward and 0.6 µL reverse Nextera XT 589
